drugset / Trial / NCT05574608
Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Phase 0
Unknown
12 enrolled
Affiliated Hospital to Academy of Military Medical Sciences
Beijing JD Biotech Co. LTD. · collab
NaSequentialOpen-labelTreatment
Summary
The CD123-Targeted CAR-NK cell therapy is a new treatment that is being investigated for treatment of acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety of CD123-CAR NK cells given to these patients.
Timeline
- Start
- 2022-10-01
- Primary completion
- 2023-10-30
- Completion
- 2024-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD123-CAR-NK | Cell therapy | 1e+07 cells/kg | Other |
| Subject | CD123-CAR-NK | Cell therapy | 1e+09 cells | Other |